- Home
- SKYH vs AARD Comparison
SKYH vs AARD Comparison
Compare SKYH & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKYH | AARD |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.6M | 281.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SKYH | AARD |
|---|---|---|
| Price | $8.88 | $12.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $13.83 | ★ $31.11 |
| AVG Volume (30 Days) | 130.1K | ★ 148.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $95.36 | N/A |
| Revenue Next Year | $69.38 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.22 | $4.88 |
| 52 Week High | $14.20 | $19.58 |
Technical Indicators
Market Signals| Indicator | SKYH | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 45.50 | 43.27 |
| Support Level | $8.28 | $11.14 |
| Resistance Level | $9.42 | $13.58 |
| Average True Range (ATR) | 0.38 | 1.05 |
| MACD | -0.05 | -0.14 |
| Stochastic Oscillator | 46.40 | 31.45 |
Price Performance
Historical ComparisonAbout SKYH Sky Harbour Group Corporation
Sky Harbour Group Corp is an aviation infrastructure company building a nationwide network of Home-based solutions for business aircraft. The company develops, leases, and manages business aviation hangars across the United States based on its proprietary targeting and acquisition model, targeting airfields with hangar supply and demand imbalances in the markets. Its hangar campuses feature exclusive private hangars and a full suite of dedicated services specifically designed for home-based aircraft.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.